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ABSTRACT 
 
Rationale  
Limited evidence from randomised controlled trials suggests that varenicline might be more 
effective than nicotine replacement therapy (NRT) in achieving abstinence from smoking. The 
comparative effectiveness of varenicline when prescribed under routine circumstances and in the 
general population has not been tested.  
 
Objectives 
To compare the abstinence rates of smokers trying to stop having used varenicline versus NRT on 
prescription (Rx) when provided with minimal professional support in the general population while 
adjusting for key potential confounders. 
 
Methods 
A large survey of a representative sample of the English population. Participants were 1,579 adults 
who smoked within the previous 12 months and made at least one quit attempt with varenicline 
or NRT Rx in their most recent quit attempt. The main outcome measure was self-reported 
abstinence up to the time of the survey, adjusted for key potential confounders including urges to 
smoke. A sensitivity analysis was conducted in subsamples in which the quit attempt started up to 
6 months or more than 6 months ago. 
 
Results 
The adjusted odds of abstinence in users of varenicline were 1.76 (95%CI=1.22-2.53) times higher 
compared with users of NRT Rx. However, there was no detectable difference in the subsample of 
smokers who started their quit attempt more than 6 months ago (adjusted OR=1.03, 95%CI=0.54-
1.96). 
 
Conclusions 
Varenicline use with minimal professional support in the general population of smokers appears 
more effective than NRT Rx in achieving short-term abstinence. However, this effect may 
disappear in the long term. Research is needed to confirm this and establish what may underlie it.   
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INTRODUCTION 
The World Health Organization (WHO) estimates that smoking kills nearly six million people each 
year and that up to half the users who do not stop will die of a tobacco-related disease.(World 
Health Organisation (WHO), 2011) Every year that someone continues to smoke after early middle 
age loses them 3 months of life expectancy.(Doll et al., 2004) It is therefore important that every 
quit attempt has the best possible chance of success. 
 
Several pharmacological treatments can improve the chance of successful quitting. Varenicline, a 
partial α4β2 receptor agonist, has been shown to be more effective than placebo and bupropion 
in achieving long-term abstinence from smoking.(Gonzales et al., 2006; Jorenby et al., 2006) Few 
randomised controlled trials, however, have directly compared the efficacy of varenicline with 
nicotine replacement therapy (NRT), which has been the most widely used smoking cessation drug 
for decades. One large-scale (N=746) multi-national trial showed that, in the context of intensive 
behavioural support, varenicline was more effective than NRT transdermal patch in achieving 
short-term (end-of-treatment) abstinence.(Aubin et al., 2008) However, this trial as well as a 
medium-scale (N=272) trial from Iran (Heydari et al., 2012) and a small-scale (N=28) trial from 
Japan (Tsukahara et al., 2010) did not provide strong evidence for the long-term superiority 
(abstinence at 6- to 12-months post-treatment).  
 
Randomised controlled trials, even what are termed "effectiveness trials" that seek to simulate as 
far as possible the routine clinical environment, need to be supplemented by "real world" studies 
in order to establish generalisability. This is because requiring informed consent to randomisation 
is potentially an important threat to external validity. Such real world studies are not a substitute 
for randomised trials, but complement them. They necessarily use epidemiological methods and 
rely on correlational evidence with statistical adjustment for potential confounding variables. 
Several cohort studies comparing the "real world" effectiveness of varenicline and NRT during 
routine treatment in clinical settings have produced mixed results.(Biazzo et al., 2010; Brose et al., 
2013; Brose et al., 2011; Dhelaria et al., 2012; Sicras Mainar et al., 2011; Stapleton et al., 2008; 
Steinberg et al., 2011) These studies often include smokers attending specialised stop-smoking 
services which limit the generalisability of findings because in the most common scenario 
medication is prescribed with only minimal professional support involving brief instructions on 
use. Furthermore, observational studies must take account of the fact that smokers who self-
select to use a certain medication may differ with regard to factors that have an effect on 
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treatment outcome, in particular their level of cigarette dependence.(Borland et al., 2012; Kotz et 
al., 2011) Another important factor is that use of pharmacological treatments to aid smoking 
cessation may be different outside of clinical trials. Users may underdose and in the case of NRT 
they may use it singly or with more than one form of NRT at the same time or consecutively. There 
is evidence that combination NRT (e.g., using transdermal patch plus a faster acting form such as 
nicotine gum) is more effective than single form.(Fiore et al., 2008; Stead et al., 2008) 
 
The current study is the first to compare the effectiveness of varenicline with NRT on prescription 
(NRT Rx) when provided with minimal professional support in the general population and while 
adjusting for key potential confounding factors.  
 
METHODS 
We used data from the "Smoking Toolkit Study", which is an ongoing research programme 
designed to provide information about smoking cessation and factors that promote or inhibit it at 
a population level.(Fidler et al., 2011a) Each month a new sample of approximately 1,800 adults in 
England aged 16 and over completes a face-to-face computer-assisted survey, of whom 
approximately 450 are smokers. The methods have been described in full elsewhere and have 
been shown to result in figures for key variables such as smoking prevalence that are nationally 
representative.(Fidler, et al., 2011a)(www.smokinginengland.info)  
 
TNS-BMRB collects the data as part of their monthly omnibus surveys on behalf of researchers at 
University College London. The surveys use a form of random location sampling. England is split 
into 165,665 Output Areas, each comprising approximately 300 households. These Output Areas 
are stratified by ACORN characteristics (an established geo-demographic analysis of the 
population; http://www.caci.co.uk/acorn) and then randomly selected to be included in the lists of 
the interviewers. Interviewers travel to the selected areas and perform interviews with one 
participant per household until quotas based upon factors influencing the probability of being at 
home (working status, age, and gender) are fulfilled. Morning interviews are avoided to maximise 
participant availability. 
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Study population 
For the current study, we used aggregated data from respondents to the survey in the period from 
November 2006 (the start of the survey) to September 2012 (the latest wave of the survey for 
which data were available), who smoked either cigarettes (including hand-rolled) or any other 
tobacco product (e.g., pipe or cigar) daily or occasionally at the time of the survey or during the 
preceding 12 months. We included those who made at least one quit attempt in the preceding 12 
months, assessed by asking: "How many serious attempts to stop smoking have you made in the 
last 12 months? By serious attempt I mean you decided that you would try to make sure you never 
smoked again. Please include any attempt that you are currently making and please include any 
successful attempt made within the last year." We also asked how long ago the most recent quit 
attempt started and categorised respondents into those who started their quit attempt in the last 
week or up to 6 months ago and those who started their quit attempt more than 6 months ago.  
 
To identify methods used to stop smoking, respondents were asked "Which, if any, of the 
following did you try to help you stop smoking during the most recent serious quit attempt?" 
Respondents could select any of the following: "nicotine replacement product on prescription or 
given to you by a health professional, Champix (varenicline), attended a stop smoking group, 
attended one or more stop smoking one-to-one counselling\advice\support session\s, nicotine 
replacement product (e.g., patches\gum\inhaler) without a prescription."  
 
We included respondents who used either varenicline or NRT on prescription (Rx) during their 
most recent quit attempt and excluded those who used these medications in combination with a 
stop smoking group or counselling (9.9% of medication users) and a nicotine replacement product 
obtained without prescription. This resulted in a sample of smokers who tried to quit with 
varenicline or NRT Rx which was assumed to be combined with minimal professional support.  
 
Measurements 
Our primary outcome was self-reported non-smoking up to the time of the survey. Respondents 
were asked: "How long did your most recent serious quit attempt last before you went back to 
smoking?". Those responding "I am still not smoking" were defined as non-smokers. Previous 
research has shown that self-reported abstinence in surveys of this kind closely reflects true 
smoking rates and is not subject to the kind of biases observed in clinical trials where there is 
social pressure to claim abstinence.(West et al., 2007; Wong et al., 2012)    
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We measured a range of variables that are potentially associated with the use of smoking 
cessation treatments and may also have an effect on the outcome. First, time spent with urges to 
smoke was assessed by asking: "How much of the time have you felt the urge to smoke in the past 
24 hours? Not at all (coded 1), a little of  the time (2), some of the time (3), a lot of the time (4), 
almost all of the time (5), all of  the time (6)". Second, strength of urges to smoke was measured 
by asking "In general, how strong have the urges to smoke been?": slight (1), moderate (2), strong 
(3), very strong (4), extremely strong (5). This question was coded "0" for smokers who responded 
"not at all" to the previous question. Different measures of dependence exist but urges to smoke 
have been found to be a better predictor of relapse than the more common Fagerström Test for 
Nicotine Dependence and its components in this particular population.(Fidler et al., 2011b) 
Demographic characteristics we took into account were age, sex, and social grade (AB = 
managerial and professional occupations, C1 = intermediate occupations, C2 = small employers 
and own account workers, D = lower supervisory and technical occupations, and E = semi-routine 
and routine occupations, never workers, and long-term unemployed). Furthermore, we measured 
the number of quit attempts in the last year prior to the one in question, time since the quit 
attempt in question was initiated, and whether smokers had tried to quit abruptly or gradually.  
 
Data analysis 
The simple associations between potential confounders and use of varenicline vs. NRT Rx were 
assessed with ANOVA for continuous variables and Pearson's χ2 for categorical variables.  
 
For the primary analysis, we used a multiple logistic regression model in which we regressed the 
outcome measure (non-smoker vs. smoker) on the effect measure (varenicline vs. NRT Rx), 
adjusted for the above mentioned potential confounders and wave of the survey. The model 
included interaction terms between time since last quit attempt and time spent with urges, and 
between time since last quit attempt and strength of urges to smoke. These two latter interaction 
terms were used to account for the fact that urges to smoke following the quit attempt will be 
influenced by whether the respondent is currently abstinent and the duration of abstinence. 
 
In a sensitivity analysis, we assessed potential differential bias in recall of quit attempts by testing 
the association between time since the last quit attempt started and type of medication used 
during that quit attempt (varenicline or NRT Rx) with Pearson's χ2. Subsequently, we ran the model 
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of the primary analysis separately for the sub-samples of smokers who started their last quit 
attempt less versus more than 6 months ago to assess any difference in short- versus long-term 
effectiveness of the two medications.  
 
All analyses were performed with complete cases. Respondents with missing data on one or more 
of the variables were excluded (5% of the initial sample). 
 
RESULTS 
The study population consisted of 1,579 respondents; 1,329 (84.2%) who smoked and 250 (15.8%) 
who were abstinent at the time of the survey. A total of 540 (34.2%) respondents had used 
varenicline and 1,039 (65.8%) had used NRT Rx during their most recent quit attempt.  
 
Associations between characteristics of the sample and use of varenicline or NRT Rx are presented 
in Table 1. There was no difference in age and sex but a non-linear association with the categories 
of social grade. NRT Rx users were more likely to have made more quit attempts in the past and to 
have stopped abruptly without cutting down first during their most recent quit attempt. They also 
reported higher levels of urges to smoke. There was no difference in time since the last quit 
attempt started. 
 
The results of our primary analysis are presented in Table 2. The adjusted odds of non-smoking in 
users of varenicline were 1.76 (95%CI=1.22-2.53) times higher compared with users of NRT Rx. 
Although there was no statistically significant interaction between time since last quit attempt and 
type of medication used during that attempt (adjusted OR=0.54, 95%CI=0.26-1.12), the table 
shows that the adjusted odds of non-smoking in users of varenicline were not different from users 
of NRT Rx in smokers who started their last quit attempt more than 6 months ago (adjusted 
OR=1.03, 95%CI=0.54-1.96).  
 
DISCUSSION 
In a national survey of the English population, use of varenicline during a quit attempt was 
associated with a 1.76 times higher rate of success compared with NRT Rx. However, in the 
subsample of smokers who started their quit attempt more than 6 months ago, varenicline did not 
appear to be associated with a higher rate of success.  
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The overall odds ratio in this study was slightly higher than those from the two published 
randomised controlled trials comparing varenicline with single form NRT (Aubin, et al., 2008; 
Heydari, et al., 2012) and larger than one small trial (Tsukahara, et al., 2010). It was also similar to 
the odds ratios for varenicline versus single form NRT from observational studies in which 
intensive behavioural support was provided (Brose, et al., 2011; Stapleton, et al., 2008). However, 
the overall odds ratio in this study was greater than has been found when varenicline has been 
compared in observational studies with combination NRT (Brose, et al., 2013; Stapleton, et al., 
2008).  
 
Although the interaction between time since last quit attempt and type of medication used was 
not statistically significant, our sensitivity analysis showed a significantly higher odds of successful 
quitting in varenicline users in the subsample who started their quit attempt less than 6 months 
ago (OR=2.20 (95%CI=1.39-3.47)). In the subsample who started their quit attempt more than 6 
months ago, however, varenicline appeared to be no better than NRT Rx (OR=1.03 (0.54-1.96)). 
There was no detectable association between time since the last quit attempt started and type of 
medication used, so it is unlikely that the latter finding is due to differential recall bias (i.e., that 
failed quit attempts that started more than 6 months ago are more likely to be forgotten when 
they were made with NRT Rx than with varenicline). If these results are unbiased, they would 
indicate that the increased effectiveness of varenicline compared with NRT Rx seen in the short-
term is not sustained in the long-term in smokers from the general population who used these 
medications without specialist behavioural support. This finding could be due to lower adherence 
to NRT Rx than to varenicline during the first months following the quit date, or by longer term use 
of NRT Rx (e.g., longer than three months; the usual duration of treatment with varenicline). 
However, it should be noted that the power to detect both the interaction and the effect in the 
subsample was low. 
 
The main limitations of this study relate to the cross-sectional survey design. The most important 
potential bias in our study is confounding by indication (the fact that smokers who self-select to 
use varenicline or NRT Rx may differ with regard to factors that have an effect on abstinence from 
smoking). We reduced the risk of confounding by adjusting for urges to smoke, age, sex, social 
grade, abrupt quitting vs. cutting down, and previous quit attempts. However, we were not able to 
measure dependence at the time of treatment initiation. We adjusted for urges to smoke at the 
time of the survey as this measure has been shown to predict relapse best in this population and 
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because we were unable to adjust for other existing measures of dependence. This approach 
could introduce bias when comparing methods of quitting that might differentially affect urges. 
However, if such bias occurred the results of an analysis adjusting for urges to smoke would 
underestimate the benefit of varenicline because varenicline appears to reduce urges to smoke 
during quitting more than NRT.(Aubin, et al., 2008) Thus, our finding that varenicline was 
associated with greater success rates cannot be explained by this.   
 
We adjusted for several potential confounders, but not all factors associated with self-selection of 
treatment were measured in our survey, such as previous use of NRT or varenicline during a quit 
attempt, physical health, mental health (Taggar et al., 2012) or psychological distress (Lawrence et 
al., 2011). The fact that those using NRT Rx had higher urges to smoke, which would be expected 
to be associated with these variables, suggests that this group may have been harder to treat. 
However, another explanation for the difference in urges to smoke between varenicline and NRT 
Rx users we observed may be that varenicline had a larger effect on reducing urges to smoke. 
Motivation to quit may also be positively associated with both use of treatment and success. 
However, population studies have generally not found an association between motivation to quit 
and success of quit attempts.(Vangeli et al., 2011) The difference in abrupt quitting vs. cutting 
down could possibly be due to spontaneous reduction of smoking during the up-titration phase in 
the indicated use of varenicline.  
 
Our survey did not contain data on the amount of professional support received by the individual 
smoker apart from smokers not endorsing the response option indicating that they had attended 
counselling/advice/support sessions. The issuing of a prescription would normally require personal 
contact with a physician which sets a lower limit on the amount of professional support received 
but it is possible that participants received support below a level that they would have regarded as 
counselling. Furthermore, we did not have information on what proportion of the respondents 
used single form or combination NRT.  
 
Regarding our outcome variable, it was not feasible in our large population study to biochemically 
validate self-reported abstinence. This would be a serious limitation in randomized controlled 
trials because of the possibility of differential likelihood of falsely claiming abstinence by 
participants in the active treatment.(West et al., 2005) However, in population surveys the 
misreporting rate is low.(West, et al., 2007; Wong, et al., 2012)  A major strength of our study is 
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the use of a large, representative sample of the English population. Our study included all smokers 
aged 16 years or older who made a quit attempt in the 12 months preceding the survey, including 
those who smoke less than 10 cigarettes per day. This subgroup constitutes one third of current 
smokers in England (Kotz et al., 2012) and is usually excluded from clinical trials.    
 
In conclusion, this study provided support for a short-term benefit for varenicline compared with 
NRT as used by the general population of smokers with limited behavioural support. However, we 
cannot be confident that this advantage is maintained long term. This is an important area for 
future research.  
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Table 1: Associations between sample characteristics and use of varenicline or NRT Rx  
Variable Varenicline 
(N=540)  
NRT Rx  
(N=1,039) 
P 
Age, mean (SD)  43.3 (13.7) 43.4 (15.9) 0.92 
Female sex 54.8 (296) 59.4 (617) 0.81 
Social grade 
 AB 
 C1 
 C2 
 D 
 E 
 
8.5 (46) 
24.4 (132) 
22.0 (119) 
21.3 (115) 
23.7 (128) 
 
9.1 (95) 
18.5 (192) 
23.6 (245) 
18.3 (190) 
30.5 (317) 
 
0.007 
Number of quit attempts in the past year 
 1   
 2   
 3   
 4 or more   
 
73.9 (399) 
18.3 (99) 
5.0 (27) 
2.8 (15) 
 
66.2 (688) 
20.8 (216) 
7.4 (77) 
5.6 (58) 
 
0.004 
Time since last quit attempt started  
 <=1 to 26 weeks   
 26 to 52 weeks   
 
58.5 (316) 
41.4 (224) 
 
61.6 (640) 
38.4 (399) 
0.24 
Stopped abruptly without cutting down first 43.2 (233) 57.4 (596) <0.001 
Time spent with urges to smoke, mean (SD) 3.1 (1.4) 3.3 (1.3) 0.004 
Strength of urges to smoke, mean (SD) 2.0 (1.3) 2.3 (1.2) <0.001 
Figures are presented as percentage within varenicline/NRT Rx (N), unless stated otherwise. Time spent with urges to 
smoke: 1 (not at all) to 6 (all the time). Strength of urges to smoke: 0 (no urges) to 5 (extremely strong urges). NRT Rx 
= nicotine replacement therapy on prescription. Social grade: AB = managerial and professional occupations, C1 = 
intermediate occupations, C2 = small employers and own account workers, D = lower supervisory and technical 
occupations, and E = semi-routine and routine occupations, never workers, and long-term unemployed.  
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Table 2: Adjusted and unadjusted odds ratio of self-reported non-smoking in the full sample and 
in the two subsamples of respondents who started their quit attempt less/more than 6 months 
ago  
Smoking cessation treatment  Unadjusted OR (95%CI) Adjusted OR (95%CI) 
Full sample (N=1,579)   
Varenicline (N=540) 
NRT Rx (reference) (N=1,039) 
1.74 (1.32-2.29) 
1 
1.76 (1.22-2.53) 
1 
Subsample: quit attempt started <6 months (N=956)   
Varenicline (N=316)  
NRT Rx (reference) (N=640)  
2.15 (1.54-3.00) 
1 
2.20 (1.39-3.47)  
1 
Subsample: quit attempt started >6 months (N=623)   
Varenicline (N=224) 
NRT Rx (reference) (N=399) 
1.19 (0.73-1.94) 
1 
1.03 (0.54-1.96) 
1 
Odds ratio (OR) adjusted for age, sex, social grade, number of quit attempts in the last year, time since last quit 
attempt started, time spent with urges to smoke, strength of urges to smoke, time since last quit attempt started * 
time spent with urges, time since last quit attempt started * strength of urges to smoke, abrupt versus gradual 
quitting, and wave of the survey. 95%CI = 95% confidence interval around OR. NRT Rx = nicotine replacement therapy 
on prescription.  
 
